PLx Pharma (NASDAQ:PLXP) Rating Lowered to Sell at ValuEngine

ValuEngine cut shares of PLx Pharma (NASDAQ:PLXP) from a hold rating to a sell rating in a research note released on Thursday, ValuEngine reports.

A number of other equities research analysts have also issued reports on the company. Janney Montgomery Scott assumed coverage on PLx Pharma in a research note on Friday, April 12th. They set a buy rating for the company. Zacks Investment Research upgraded PLx Pharma from a sell rating to a hold rating in a report on Wednesday, June 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The company presently has an average rating of Hold.

Shares of PLXP stock traded down $0.03 on Thursday, reaching $6.00. 1,337 shares of the company’s stock were exchanged, compared to its average volume of 11,255. PLx Pharma has a 52 week low of $1.00 and a 52 week high of $7.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 4.86 and a current ratio of 4.86. The business has a fifty day moving average of $6.24.

PLx Pharma (NASDAQ:PLXP) last issued its quarterly earnings results on Friday, May 10th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.03). PLx Pharma had a positive return on equity of 31.28% and a negative net margin of 1,507.67%. The business had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, sell-side analysts forecast that PLx Pharma will post -1.28 EPS for the current year.

In other news, insider Michael J. Valentino acquired 44,404 shares of PLx Pharma stock in a transaction on Monday, May 20th. The shares were bought at an average cost of $5.60 per share, for a total transaction of $248,662.40. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 7.79% of the company’s stock.

An institutional investor recently bought a new position in PLx Pharma stock. Nottingham Advisors Inc. purchased a new stake in shares of PLx Pharma Inc (NASDAQ:PLXP) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 58,584 shares of the biotechnology company’s stock, valued at approximately $422,000. Nottingham Advisors Inc. owned about 0.66% of PLx Pharma at the end of the most recent quarter. 21.89% of the stock is owned by institutional investors and hedge funds.

PLx Pharma Company Profile

PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.

Further Reading: What does a dividend yield signify to investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.